DALLAS, Texas, April 20, 2010 The report on BRIC DiabetesDrugs Market(http://www.marketsandmarkets.com/Market-Reports/bric-diabetes-199.html)analyzes the market for oral drugs and injectables in BRIC economies over theperiod 2009 to 2014. The report measures and forecasts the BRIC market fordiabetes drugs; and analyzes the major market drivers, restraints, andopportunities.
Browse more than 15 market data tables and in-depth TOC on BRIC DiabetesDrugs Market. Early buyers will receive 10% customization of reports.
The BRIC diabetes drugs market is expected to grow from $3.9 billion in2009 to reach $8.7 billion by 2014, growing at a CAGR of 17.1% from 2009 to2014. Oral drugs accounted for around 65% of the market in 2009, butinjectables are expected to have a higher CAGR of 21.9%.
The slowdown of the pharma market growth in developed economies hasconcentrated investor interest on BRIC nations, where the diabetes drugmarket has benefitted significantly from government initiatives for spreadingpatient awareness, and the subsequent increase in the uptake of novel drugssuch as incretin mimetics (Eli Lilly's Byetta) and dipeptidyl inhibitors(Merck's Januvia and Novartis' Galvus).
SCOPE AND FORMAT
The report analyzes the BRIC Diabetes Drugs market into the followingsegments:
In addition to market tables for each submarket, each section of thereport will provide market trends, drivers, and opportunities. The reportalso draws a competitive landscape, profiling the key players and thetop-selling products in the diabetes drug market in BRIC.
Analyst Briefing Presentation on the BRIC Diabetes Drugs Market to beheld on 4th May 2010
The Healthcare practice at MarketsandMarkets is pleased to announce itsAnalyst Briefing Presentation on the BRIC Diabetes Drugs Market to be held on4th May 2010. This analyst briefing focuses on the BRIC diabetes drugs marketover the period 2009 to 2014. The agenda for the briefing includes adiscussion on key high-growth markets, identifying the growth trends inproducts and services. The briefing will also cover the market's competitivescenario and trends and opportunities in the macro- and micro-markets ofBrazil, Russia, India, and China.
To register your participation, please click here.http://www.marketsandmarkets.com/AnalystBriefing/BRIC-Diabetes-Drugs.asp
MarketsandMarkets (M&M) is a global market research and consultingcompany based in the U.S. We publish strategically analyzed market researchreports and serve as a business intelligence partner to Fortune 500 companiesacross the world. MarketsandMarkets also provides multi-client reports,company profiles, databases, and custom research services.
M&M covers thirteen industry verticals, including advanced materials,automotive and transportation, banking and financial services, biotechnology,chemicals, consumer goods energy and power, food and beverages, industrialautomation, medical devices, pharmaceuticals, semiconductor and electronics,and telecommunications and IT. Browse all our titles athttp://www.marketsandmarkets.com.- Injectables Market: (Insulin, exenatide) - Oral Drugs Market: (Metformin, sulfonylureas, thaizolidinediones, dipeptidyl inhibitors, meglitinides, alpha glucosidase inhibitors, combination medications)
SOURCE Markets and Markets